Dual Activities of Galectin-3 in Human Prostate Cancer: Tumor Suppression of Nuclear Galectin-3 Vs Tumor Promotion of Cytoplasmic Galectin-3
Overview
Affiliations
Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.
Bcl-2 and galectin-3 expression is associated with recurrence of ameloblastoma.
Mahdavi N, Saffar H, Derakhshan S, Saffar H, Heidari N Dent Res J (Isfahan). 2025; 21():69.
PMID: 39802810 PMC: 11722749. DOI: 10.4103/drj.drj_706_23.
Vascular galectins in tumor angiogenesis and cancer immunity.
Thijssen V Semin Immunopathol. 2024; 46(1-2):3.
PMID: 38990363 PMC: 11239785. DOI: 10.1007/s00281-024-01014-9.
Silvestri R, Zallocco L, Corrado A, Ronci M, Aceto R, Ricci B Front Genet. 2024; 15:1380495.
PMID: 38933925 PMC: 11199678. DOI: 10.3389/fgene.2024.1380495.
Tumor-Intrinsic Galectin-3 Suppresses Melanoma Metastasis.
Mohammed N, Lau L, Souchak J, Qiu S, Ahluwalia M, Osman I J Invest Dermatol. 2024; 144(9):2039-2051.e9.
PMID: 38458429 PMC: 11344686. DOI: 10.1016/j.jid.2024.02.011.
Targeting intracellular galectins for cancer treatment.
Nehme R, St-Pierre Y Front Immunol. 2023; 14:1269391.
PMID: 37753083 PMC: 10518623. DOI: 10.3389/fimmu.2023.1269391.